Trial record 28 of 435 for:    hepatitis b | Open Studies

A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2008 by Huntington Medical Research Institutes.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
InterMune
Information provided by:
Huntington Medical Research Institutes
ClinicalTrials.gov Identifier:
NCT00753467
First received: September 15, 2008
Last updated: October 20, 2010
Last verified: September 2008
  Purpose

Open-label, prospective, two part study evaluating IFN-γ 1b at a dose of 200μg by subcutaneous injection every day either alone or in combination with Adefovir dipivoxil or Adefovir dipivoxil alone at a dose of 10mg QD in patients with chronic Hepatitis B.


Condition Intervention Phase
Hepatitis B
Drug: IFN-γ 1b (Actimmune)
Drug: Adefovir dipivoxil
Drug: IFN-γ 1b and Adefovir dipivoxil combination
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Protocol Title: A Phase II Open-labeled Study to Determine the Safety and Preliminary Efficacy of Interferon-gamma 1b (IFN-γ 1b) in Patients With Chronic Hepatitis B Who Are HBV DNA Positive

Resource links provided by NLM:


Further study details as provided by Huntington Medical Research Institutes:

Primary Outcome Measures:
  • The primary objective is to evaluate the safety and tolerability of IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluate the changes in serum HBV DNA concentrations following administration of Adefovir dipivoxil alone, IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B. [ Time Frame: 30 days ] [ Designated as safety issue: No ]
  • Evaluate the changes in liver tests and hematology following administration of Adefovir dipivoxil alone, IFN-γ 1b either alone or in combination with Adefovir dipivoxil in patients with chronic Hepatitis B. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: September 2008
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
Drug: IFN-γ 1b (Actimmune)
IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
Other Names:
  • Interferon gamma
  • Actimmune
  • Immune Interferon
  • IFN-gamma
Experimental: 2
IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
Drug: IFN-γ 1b and Adefovir dipivoxil combination
IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Other Names:
  • Actimmune
  • Interferon gamma
  • IFN gamma
  • Immune Interferon
  • Hepsera
Active Comparator: 3
Adefovir dipivoxil monotherapy (10 mg QD) 30 days
Drug: Adefovir dipivoxil
Adefovir dipivoxil: 1 tablet of 10mg given orally QD
Other Name: Hepsera

Detailed Description:

After signing the informed consent potential patients will undergo a screening medical history, physical examination, and laboratory tests.

The study will consist of two parts:

  • Part A: IFN-γ 1b monotherapy
  • Part B: IFN-γ 1b combination therapy with Adefovir dipivoxil or Adefovir dipivoxil monotherapy

Patients will be enrolled sequentially into to one of three treatment groups. In Part A, ten patients will be enrolled and will receive IFN-γ 1b 200μg, administered every day by subcutaneous injection for 4 weeks. If HBV DNA is reduced by ≥ 1 log10 copies/ mL in ≥ 30% of patients the protocol will proceed to Part B.

In Part B, twenty patients will be enrolled into two cohorts (total of 10 for each cohort) and treated for four weeks. The two cohorts will be administered:

  • IFN-γ 1b 200μg, administered every day combination therapy with Adefovir dipivoxil (10mg QD) or
  • Adefovir dipivoxil (10mg QD) alone

On the initial study visit, patients will be given instruction on self injection of IFN-γ 1b (if applicable). Patients will be monitored for safety, tolerability, HBV DNA, clinical chemistries including a standard panel of liver tests and hematologies throughout the study and for the two week post-treatment observation period.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients must fulfill all of the following criteria to be eligible for enrollment into the study:

  1. Men or women age 18 to 75 years
  2. Chronic hepatitis B infection based on a history of positive anti-HBsAg and positive for HBV DNA and with or without elevations in liver tests (test to be repeated on screening)

Exclusion Criteria:

Patients with any of the following will be excluded from randomization:

  1. Presence of clinically evident cirrhosis including: ascites requiring active diuretic therapy, history of or therapy for hepatic encephalopathy, or history of GI variceal bleeding
  2. Platelet count < 50,000/mm3
  3. Serum ALT level > 10 times upper limit of normal
  4. Alpha-fetoprotein level ≥ 200 ng/mL or alpha-fetoprotein level between 50-200 ng/mL in association with liver ultrasound or other radiographic abnormality suspicious for hepatic neoplasm
  5. Serum creatinine level > 1.6 mg/dL
  6. Hematology outside of specified limits: neutrophil count <1000/mm3, hemoglobin <10 g/dL in males and <9 g/dL in females
  7. Unstable or uncontrolled thyroid disease
  8. Treatment with any interferon-α or nucleoside/tide analog within the previous 4 weeks
  9. Presence of clinically significant cryoglobulinemia (e.g., skin rash, arthritis, or renal insufficiency due to cryoglobuliemia)
  10. Presence or history of autoimmune hepatitis, alpha-1 anti-trypsin deficiency, hemochromatosis, Wilson's disease, drug- or toxin-induced liver disease, alcohol-related liver disease, primary biliary cirrhosis, or sclerosing cholangitis (mild-to-moderate steatosis is acceptable)
  11. Chronic hepatitis C infection
  12. Hepatits Delta infection (HDV)
  13. Known history of HIV infection or positive HIV antibody test by Western Blot (test performed within 60 days of screening can be used to determine eligibility)
  14. A disease known to cause significant alteration in immunologic function including hematological malignancy or autoimmune disorder (e.g. rheumatoid arthritis, systemic lupus erythematosis, autoimmune thyroid disease, leukemia, lymphoma, etc)
  15. Concurrent therapy with immunosuppressive drugs or cytotoxic agents such as oral prednisone, cyclosporine, azathioprine, or chemotherapeutic agent(s) (e.g., cyclophosphamide, methotrexate, or cancer chemotherapy) or radiation therapy
  16. Behavior that suggests a significant risk of poor compliance including, but not limited to:

    1. Illicit drug abuse within the past 3 years
    2. Current or history of alcohol abuse within the past 2 years
  17. Prior treatment with IFN-γ 1b
  18. History of unstable or deteriorating cardiac disease, including but not limited to:

    1. Myocardial infarction, coronary artery bypass surgery, or angioplasty within the past 6 months
    2. Congestive heart failure requiring hospitalization within the past 6 months
    3. Uncontrolled arrhythmias
    4. Transient ischemic attacks (TIAs)
    5. Any cardiac condition that, in the opinion of the site PI, might be significantly exacerbated by flu-like symptoms associated with the administration of IFN γ 1b
  19. Preexisting (within last two years) or active psychiatric condition including severe depression, major psychoses, suicidal ideation or suicidal attempts
  20. History of (within last two years) or current neurologic or psychiatric disorder that, in the opinion of the site PI, might be exacerbated by flu-like symptoms associated with the administration of IFN γ 1b. In addition, patients with the following conditions should be excluded:

    1. History of multiple sclerosis
    2. Seizures within the past 2 years
  21. Severe or poorly controlled diabetes
  22. Pregnancy or lactation. Females of childbearing potential are required to have a negative urine pregnancy test prior to treatment and must agree to practice abstinence or prevent pregnancy by at least a barrier method of birth control for the duration of the study
  23. Hemoglobinopthies (e.g. thalassemia, sickle cell disease)
  24. Any serious or chronic disease that, in the opinion of the Principal Investigator (PI), may affect the assessment of safety or efficacy parameters. This includes, but is not limited to, patients with malignancy who are receiving chemotherapy, chronic obstructive pulmonary disease or asthma requiring maintenance oral steroids, or active kidney disease
  25. Any condition which, in the opinion of the site PI, is likely to result in the death of the patient within the next year
  26. Patients who, in the opinion of the site PI, are not suitable candidates for enrollment or would not comply with the requirements of the study
  27. Patients who have had a liver transplant
  28. Patients who have Adefovir mutations on baseline tests
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00753467

Locations
United States, California
Huntington Medical Research Institutes Not yet recruiting
Pasadena, California, United States, 91105
Contact: Lori Tong, RN    626-397-5827    ltong@hmri.org   
Principal Investigator: Myron J Tong, PhD, MD         
Sponsors and Collaborators
Huntington Medical Research Institutes
InterMune
Investigators
Study Chair: Myron J Tong, Phd, MD HMRI
  More Information

Additional Information:
Publications:

Responsible Party: Myron Tong, PhD, MD, HMRI
ClinicalTrials.gov Identifier: NCT00753467     History of Changes
Other Study ID Numbers: TONG-HBV-0801
Study First Received: September 15, 2008
Last Updated: October 20, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Huntington Medical Research Institutes:
HBV
Treatment
Interferon-gamma
combination
Hepsera
Actimmune
HBV DNA

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Hepatitis, Viral, Human
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Adefovir
Adefovir dipivoxil
Interferon-gamma
Interferons
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014